Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 11:00 a.m. ET at The Waldorf Astoria Hotel in New York, NY… Read more »
Shares of Galena Biopharma closed yesterday at $1.71 . GALE has a 1-year high of $5.70 and a 1-year low of $1.43. The stock’s 50-day moving average is $1.62 and it’s 200-day moving average is $2.08.
On the ratings front, Galena Biopharma (NASDAQ: GALE has been the subject of a number of recent research reports. In a report issued on January 20, MLV & Co. analyst Vernon Bernardino reiterated a Buy rating on GALE, with a price target of $5, which implies an upside of 192.4% from current levels. Separately, on January 16, Maxim Group`s Jason Kolbert maintained a Buy rating on the stock and has a price target of $7.
In total, one research analyst has assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $1.71 which is 290.1% above where the stock closed yesterday.
Galena Biopharma Inc, is a biopharmaceutical company focused on developing and commercializing, targeted treatments that address unmet medical needs to advance cancer care.